Compare Autodesk Inc (ADSK) vs Alnylam Pharmaceuticals, Inc. (ALNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Autodesk Inc vs Alnylam Pharmaceuticals, Inc. — how do they compare? Autodesk Inc trades at $249 (market cap $53.12B), while Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B). The key difference: Autodesk Inc is the larger of the two by market cap, and Autodesk Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ADSK | ALNY | |
|---|---|---|
Market Cap | $53.12B | $29.60B |
Sector | Technology | Health |
52-Week High | $326.79 | $491.22 |
52-Week Low | $187.72 | $205.48 |
Enterprise Value | $52.92B | $27.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Autodesk (ADSK) trades at $249.55, down 2.55% today, but maintains a strong fundamental profile with robust earnings beats, including Q1 2026 EPS of $2.99 versus $2.84 expected. The stock exhibits a bullish technical trend with moving averages supporting upside, though RSI levels indicate potential overbought conditions. Revenue growth is steady, projected to reach $7.5B in 2026, with a high net income margin of 19.49% in 2025.
The outlook remains positive given analyst consensus favoring Buy ratings (74.51%) and a $302.23 price target, implying significant upside. Key risks include competitive pressures in design software and reliance on enterprise spending cycles. Continued execution on AI investments and margin expansion are critical for sustaining valuation multiples.
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Autodesk Inc
Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction.
Read more on ADSK →About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →
